The effect of magnesium sulfate treatment on blood biochemistry and bleeding time in patients with severe preeclampsia

Güzin, Kadir; Göynümer, Gökhan; Gokdagli, Fulya; Türkgeldi, Engin; Gunduz, Gunes; Kayabasoglu, Furkan

doi:10.3109/14767050903156684

Cited by 12 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Full texts of 50 of these 53 studies (three could not be located) were retrieved and assessed. Twenty‐eight studies published over a span of seven decades and conducted in the Americas, Europe, Asia, and sub‐Saharan Africa met the inclusion criteria . The studies involved a total of 1466 women with pre‐eclampsia and/or eclampsia.…”

Section: Resultsmentioning

confidence: 99%

“…Overall, 12 studies were assessed to be at low risk of bias, 13 at uncertain risk of bias and 3 at high risk of bias . For 23 studies that examined intravenous regimens, 10 were assessed to be at low risk of bias, 11 at uncertain risk of bias and two at high risk of bias . For the nine studies that examined only intramuscular regimens, three studies were assessed to be at low risk of bias five at uncertain risk of bias and one at high risk of bias…”

Section: Resultsmentioning

confidence: 99%

“…Six studies provided sparse pharmacokinetic data based on this regimen . The reported baseline serum magnesium values were between 0.58 and 0.80 mmol/l .…”

Section: Resultsmentioning

confidence: 99%

“…Six studies provided sparse pharmacokinetic data based on this regimen . The reported baseline serum magnesium values were between 0.58 and 0.80 mmol/l . Following initiation of MgSO4, one study showed that this level doubled in ½ hour before declining slightly to plateau between 1.70 and 1.80 mmol/l between 1 hour and 12 hours of maintenance infusion .…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Clinical pharmacokinetic properties of magnesium sulphate in women with pre‐eclampsia and eclampsia

Okusanya

Oladapo

Long

et al. 2015

BJOG

104

View full text Add to dashboard Cite

BackgroundThe pharmacokinetic basis of magnesium sulphate (MgSO 4) dosing regimens for eclampsia prophylaxis and treatment is not clearly established.ObjectivesTo review available data on clinical pharmacokinetic properties of MgSO 4 when used for women with pre‐eclampsia and/or eclampsia.Search strategy MEDLINE, EMBASE, CINAHL, POPLINE, Global Health Library and reference lists of eligible studies.Selection criteriaAll study types investigating pharmacokinetic properties of MgSO 4 in women with pre‐eclampsia and/or eclampsia.Data collection and analysisTwo authors extracted data on basic pharmacokinetic parameters reflecting the different aspects of absorption, bioavailability, distribution and excretion of MgSO 4 according to identified dosing regimens.Main resultsTwenty‐eight studies investigating pharmacokinetic properties of 17 MgSO 4 regimens met our inclusion criteria. Most women (91.5%) in the studies had pre‐eclampsia. Baseline serum magnesium concentrations were consistently <1 mmol/l across studies. Intravenous loading dose between 4 and 6 g was associated with a doubling of this baseline concentration half an hour after injection. Maintenance infusion of 1 g/hour consistently produced concentrations well below 2 mmol/l, whereas maintenance infusion at 2 g/hour and the Pritchard intramuscular regimen had higher but inconsistent probability of producing concentrations between 2 and 3 mmol/l. Volume of distribution of magnesium varied (13.65–49.00 l) but the plasma clearance was fairly similar (4.28–5.00 l/hour) across populations.ConclusionThe profiles of Zuspan and Pritchard regimens indicate that the minimum effective serum magnesium concentration for eclampsia prophylaxis is lower than the generally accepted level. Exposure–response studies to identify effective alternative dosing regimens should target concentrations achievable by these standard regimens.Tweetable abstractMinimum effective serum magnesium concentration for eclampsia prophylaxis is lower than the generally accepted therapeutic level.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Six studies provided sparse pharmacokinetic data based on this regimen . The reported baseline serum magnesium values were between 0.58 and 0.80 mmol/l .…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical pharmacokinetic properties of magnesium sulphate in women with pre‐eclampsia and eclampsia

Okusanya

Oladapo

Long

et al. 2015

BJOG

104

View full text Add to dashboard Cite

show abstract

“…In the study of Maged et al, [8], the mean age of the studied mothers was 26.82 ± 6.31years. The mean of their gravidity was1.66 ± 1.75.…”

Section: Discussionmentioning

confidence: 89%

Determining the effect of Magnesium Sulfate on Doppler Parameters of Fetal Umbilical and Middle Cerebral Arteries in Women with Severe Preeclampsia: A Prospective Study

Okab

Omar

Mashaly

et al. 2021

JAMMR

View full text Add to dashboard Cite

Background: Preeclampsia is best described as a pregnancy-specific syndrome that can affect every organ system. Although preeclampsia is much more than simply gestational hypertension with proteinuria, appearance of proteinuria remains an important objective diagnostic criterion. The aim of this study is to evaluate Doppler velocimetric parameters (resistance index [RI], pulsatility index [PI], and systolic/diastolic [S/D] ratio) of the umbilical and middle cerebral arteries before and after magnesium sulfate administration in pregnant women with severe preeclampsia. Methods: This prospective study had been included 25 women from the emergency department and Obstetrics outpatient clinic Tanta University. Resistance index [RI], pulsatility index [PI] and systolic/ diastolic [S/D] ratio of middle cerebral artery and umbilical artery before and 20 minutes after intravenous administration of 6 grams of magnesium sulfate (loading dose). Results: The maternal age of cases included in the study ranged between 18 year and 40 year with a mean age of 32.03±6.1. The gravidity of cases included in the study ranged between 1 and 5 with a mean of 2.01±1.03.The parity of cases included in the study ranged between 0 and 6 with a mean of 2.18±1.04.The number of abortions ranged between 0 and 3whith a mean of 0.61±0.03. The serum level of ALT ranged between 11 and 104 mEq/L with a mean of 49.12±27.81. The serum level of AST ranged between 13 and 84 mEq/L with a mean of 42.5±20.17. The resistance index (RI) before MgSo4 administration ranged between 0.45 and 1.0 with a mean of 0.65 ± 0.15while it ranged between 0.4 and 0.9 after MgSo4 administration with a mean of 0.63± 0.13 .There was statistical significant differences between them (p<0.001). The pulsatility index (PI) before MgSo4 administration ranged between 0.6 and 2.15 with a mean of 1.15±0.45 while it ranged between 0.5 and 0.2 after MgSo4 administration with a mean of 1.04± 0.45 .There was statistical significant differences between them (p<0.001) . Conclusions: Infusion of MgSO4 significantly decreases the fetal RI-umbilical and PI-MCA and increases C/U ratio indices obtained with color Doppler ultrasound evaluations.

show abstract

Effects of perioperative magnesium sulfate with controlled hypotension on intraoperative bleeding and postoperative ecchymosis and edema in open rhinoplasty

Koşucu

Tuğcugil

Arslan

et al. 2020

American Journal of Otolaryngology

View full text Add to dashboard Cite

The effect of magnesium sulfate treatment on blood biochemistry and bleeding time in patients with severe preeclampsia

Abstract: Magnesium sulfate infusion prolonged bleeding time in patients with severe preeclampsia. This is clinically important because it worsens the present condition and causes possible complications.

Cited by 12 publications

References 18 publications

Clinical pharmacokinetic properties of magnesium sulphate in women with pre‐eclampsia and eclampsia

Clinical pharmacokinetic properties of magnesium sulphate in women with pre‐eclampsia and eclampsia

Determining the effect of Magnesium Sulfate on Doppler Parameters of Fetal Umbilical and Middle Cerebral Arteries in Women with Severe Preeclampsia: A Prospective Study

Effects of perioperative magnesium sulfate with controlled hypotension on intraoperative bleeding and postoperative ecchymosis and edema in open rhinoplasty

Contact Info

Product

Resources

About